The estimated Net Worth of Robert P Ragusa is at least $6.55 Million dollars as of 3 March 2021. Mr. Ragusa owns over 10,588 units of Twist Bioscience Corp stock worth over $553,879 and over the last 12 years he sold TWST stock worth over $5,908,022. In addition, he makes $89,747 as Independent Director at Twist Bioscience Corp.
Sign up
Mr. Ragusa TWST stock SEC Form 4 insiders trading
Robert has made over 10 trades of the Twist Bioscience Corp stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 10,588 units of TWST stock worth $321,981 on 3 March 2021.
The largest trade he's ever made was exercising 10,588 units of Twist Bioscience Corp stock on 3 March 2021 worth over $321,981. On average, Robert trades about 1,978 units every 30 days since 2013. As of 3 March 2021 he still owns at least 12,486 units of Twist Bioscience Corp stock.
You can see the complete history of Mr. Ragusa stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Robert Ragusa biography
Robert Ragusa serves as Independent Director of the Company. Mr. Ragusa is currently the Senior Vice President, Global Quality and Operations, at Illumina, Inc., a strategic commercial partner of Twist and a publicly traded corporation, where he has worked since December 2013. Prior to joining Illumina, Inc., from April 2010 to November 2013, Mr. Ragusa was Executive Vice President, Global Operations and Service at Accuray Incorporated, a radiation oncology company that develops, manufactures, sells and supports cancer treatment solutions. Mr. Ragusa holds a B.S. in Biomedical and Electrical Engineering and an M.B.A. from the University of Connecticut, and an M.S. in Biomedical and Electrical Engineering from Carnegie-Mellon University. Our board of directors believes that Mr. Ragusa brings extensive experience in important ecosystem partners and managing operations of large public companies, and this, in addition to his education in biotechnology, finance and management, qualifies him to serve as one of our directors.
What is the salary of Robert Ragusa?
As the Independent Director of Twist Bioscience Corp, the total compensation of Robert Ragusa at Twist Bioscience Corp is $89,747. There are 11 executives at Twist Bioscience Corp getting paid more, with Emily Leproust having the highest compensation of $8,126,160.
How old is Robert Ragusa?
Robert Ragusa is 60, he's been the Independent Director of Twist Bioscience Corp since 2017. There are 6 older and 17 younger executives at Twist Bioscience Corp. The oldest executive at Twist Bioscience Corp is Dr. William Charles Banyai Ph.D., 66, who is the Sr. VP of Advanced Devel., GM of Data Storage & Director.
What's Robert Ragusa's mailing address?
Robert's mailing address filed with the SEC is Illumina, University City, San Diego, San Diego County, California, United States of America.
Insiders trading at Twist Bioscience Corp
Over the last 6 years, insiders at Twist Bioscience Corp have traded over $141,837,821 worth of Twist Bioscience Corp stock and bought 168,550 units worth $2,482,088 . The most active insiders traders include Fred B Craves, Keith Crandell und Emily M. Leproust. On average, Twist Bioscience Corp executives and independent directors trade stock every 8 days with the average trade being worth of $465,824. The most recent stock trade was executed by Dennis Cho on 6 September 2024, trading 275 units of TWST stock currently worth $10,769.
What does Twist Bioscience Corp do?
at twist bioscience, our expertise is synthetic dna. we have developed a proprietary semiconductor-based synthetic dna manufacturing process featuring a 10,000-well silicon platform capable of producing synthetic biology tools, such as oligonucleotides, genes, pathways, chassis and genomes. by synthesizing dna on silicon instead of on traditional 96-well plastic plates, our platform overcomes the current inefficiencies of synthetic dna production, and enables cost-effective, rapid, high-quality and high throughput synthetic gene production. the twist bioscience platform has the potential to greatly accelerate the development of personalized medicine, sustainable chemical production, improved agriculture production as well as new applications such as in vivo diagnostics, biodetection and data storage. for more information, please visit www.twistbioscience.com .
What does Twist Bioscience Corp's logo look like?
Complete history of Mr. Ragusa stock trades at Accuray Inc, Illumina Inc und Twist Bioscience Corp
Twist Bioscience Corp executives and stock owners
Twist Bioscience Corp executives and other stock owners filed with the SEC include:
-
Emily Leproust,
Chairman of the Board, President, Chief Executive Officer -
James Thorburn,
Chief Financial Officer -
Patrick Finn,
Chief Commercial Officer -
Dr. Emily Marine Leproust Ph.D.,
Co-Founder, Chairman, Pres & CEO -
Patrick Weiss,
Chief Operating Officer -
James M. Thorburn,
Chief Financial Officer -
Dr. Patrick John Finn Ph.D.,
Chief Commercial Officer -
Mark Daniels,
Senior Vice President, Chief Legal Officer, Chief Ethics and Compliance Officer and Secretary -
Dr. William Charles Banyai Ph.D.,
Sr. VP of Advanced Devel., GM of Data Storage & Director -
Jan Johannessen,
Independent Director -
Nelson Chan,
Independent Director -
Robert Ragusa,
Independent Director -
Keith Crandell,
Independent Director -
Robert Chess,
Lead Independent Director -
Xiaoying Mai,
Independent Director -
Nicolas Barthelemy,
Independent Director -
William Banyai,
Director -
Paula Green,
Vice President of Human Resources -
Bill Peck,
Chief Technology Officer -
Erin Smith,
Senior Vice President - Government affairs and Public policy -
Martin Kunz,
Senior Vice President - Operation -
Patrick Weiss,
Chief Operating Officer -
Tracey Mullen M.B.A.,
Sr. VP of Operations -
Paula Green,
Sr. VP of HR -
Dennis Cho,
Sr. VP, Gen. Counsel, Chief Ethics & Compliance Officer -
Kevin B. Yankton,
VP & Chief Accounting Officer -
Mark Daniels Esq.,
Sr. VP, Chief Legal Officer, Chief Ethics & Compliance Officer and Sec. -
Dr. Aaron K. Sato,
Chief Scientific Officer & Chief Scientific Officer of BioPharma -
Siyuan Chen,
Chief Technology Officer -
Adam Laponis,
Chief Financial Officer -
Alpha Fund L.P. Ever,
10% owner -
Fred B Craves,
Director -
Venture Partners Viii, Llca...,
-
Melissa A. Starovasnik,
-
Dennis Cho,
See Remarks -
Kevin Bruce Yankton,
Chief Accounting Officer -
Robert F. Werner,
Chief Accounting Officer